GlobeImmune, Inc. (GBIM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGlobeImmune, Inc. (GBIM) trades at $0.0001. GlobeImmune, Inc. is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for GBIM: GBIM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
GlobeImmune, Inc. (GBIM) Healthcare & Pipeline Overview
GlobeImmune, Inc. is a biopharmaceutical company leveraging its proprietary Tarmogen platform to develop therapeutic products for cancer and infectious diseases. Headquartered in Louisville, Colorado, the company is advancing multiple candidates, including GS-4774 for hepatitis B and GI-4000 for various cancers, through clinical trials, supported by strategic collaborations.
What Is the Investment Thesis for GBIM?
GlobeImmune, Inc. presents a research-stage investment profile centered on its proprietary Tarmogen platform and a diverse pipeline targeting oncology and infectious diseases. The company's value drivers include the potential clinical success of its lead candidates, such as GS-4774 for hepatitis B and GI-4000 for various cancers, which are currently in Phase 2 and Phase 2b trials. Strategic collaborations with Gilead Sciences and Celgene Corporation provide external validation and potential pathways for advanced development and commercialization, mitigating some of the R&D burden for a company with only two employees. The breadth of its pipeline, spanning multiple therapeutic areas from chronic viral infections to various solid tumors, offers multiple shots on goal. However, the company's current market capitalization of $0.00B and a profit margin of -42.8% reflect its early-stage, development-heavy nature and lack of commercialized products. The highly negative Beta of -200.46 indicates extreme historical volatility and an inverse relationship to broader market movements, suggesting significant speculative risk. Future catalysts are heavily reliant on positive clinical trial outcomes and the progression of its pipeline through regulatory milestones.
Based on FMP financials and quantitative analysis
GBIM Key Highlights
GlobeImmune, Inc. operates with a lean structure, employing only 2 individuals, indicating a highly focused R&D model reliant on external collaborations.
- The company maintains a gross margin of 59.0%, which is notable for a biopharmaceutical company, despite a negative profit margin of -42.8% due to significant R&D expenditures.
- GlobeImmune's market capitalization is reported as $0.00B, reflecting a very low valuation typical of companies in early-stage development with no commercialized products.
- The company's Beta is an extreme -200.46, suggesting an exceptionally high degree of inverse volatility relative to the broader market, which is highly unusual for any publicly traded entity.
- GlobeImmune has established strategic collaborations with major pharmaceutical companies, Gilead Sciences, Inc. and Celgene Corporation, for the development of its therapeutic candidates.
Who Are GBIM's Competitors?
GBIM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GBIM's Key Strengths?
Proprietary Tarmogen platform with potential for diverse therapeutic applications.
- Pipeline includes multiple candidates in Phase 2/2b clinical trials for significant diseases.
- Strategic collaborations with major pharmaceutical companies (Gilead, Celgene).
- Focus on high-unmet-need areas like chronic hepatitis B and various cancers.
What Are GBIM's Weaknesses?
Extremely small operational team of 2 employees.
- Negative profit margin and reported $0.00B market capitalization, indicating limited financial resources.
- Reliance on successful clinical trial outcomes, which are inherently uncertain.
- No commercialized products or revenue streams from product sales yet.
What Are the Key Risks for GBIM?
Financial-distress signal — its Altman Z-Score of -31.84 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-64.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High clinical trial failure rates inherent in biopharmaceutical development, particularly for early-stage companies.
- Significant capital requirements for R&D, potentially leading to further dilution or financial distress given the current market capitalization.
- Intense competition from larger, better-funded pharmaceutical and biotechnology companies with similar or more advanced therapies.
- Reliance on strategic partners (Gilead, Celgene) for funding, expertise, and commercialization, with potential for partnership termination or unfavorable terms.
- Regulatory risks and lengthy approval processes, which can delay or prevent market entry for product candidates.
- Liquidity challenges and extreme volatility associated with trading on the 'OTC Other' market, coupled with unknown disclosure status.
What Are GBIM's Competitive Advantages?
- **Proprietary Tarmogen Platform:** The company's core Tarmogen platform represents a unique technological approach to stimulating T-cell immune responses, potentially offering differentiated therapeutic mechanisms.
- **Diverse Clinical Pipeline:** A broad pipeline spanning multiple oncology indications and infectious diseases provides multiple opportunities for clinical success and market penetration.
- **Strategic Collaborations:** Partnerships with established pharmaceutical companies like Gilead Sciences and Celgene Corporation provide access to significant resources, expertise, and market reach, which are difficult for small biotechs to replicate independently.
- **Intellectual Property:** Patents surrounding the Tarmogen platform and specific product candidates offer a degree of protection against direct competition.
- **Specialized Expertise:** A highly focused team, albeit small, with specialized knowledge in immunology and biopharmaceutical development, is critical for advancing complex therapeutic programs.
What Does GBIM Do?
GlobeImmune, Inc., founded in 1995 and headquartered in Louisville, Colorado, is a biopharmaceutical company dedicated to the discovery and development of therapeutic products for oncology and infectious diseases. The company's core technological foundation is its proprietary Tarmogen platform, which is designed to stimulate specific T-cell immune responses. Initially incorporated as Ceres Pharmaceuticals, Inc., the company rebranded to GlobeImmune, Inc. in May 2001, signaling its focused shift towards immunotherapeutic development. GlobeImmune's pipeline features several product candidates in various stages of clinical development. Notably, GS-4774 is currently in Phase 2 trials for patients chronically infected with hepatitis B virus, including those on oral antiviral suppressive therapy. In the oncology space, GI-6301 is being developed for cancers expressing the brachyury protein, while GI-6207 is in Phase 2 clinical trials targeting medullary thyroid cancer. A significant part of its oncology efforts involves GI-4000, which is in Phase 2b clinical trials for resected pancreas cancer and also in Phase 2 clinical trials for non-small cell lung cancer and colorectal cancer. Beyond these advanced programs, GlobeImmune maintains a preclinical pipeline addressing infectious diseases, including GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infection. The company has established strategic collaborations with prominent pharmaceutical firms, including Gilead Sciences, Inc. and Celgene Corporation, which are crucial for the development and potential commercialization of its product candidates. With a lean operational structure, the company employs two individuals, underscoring its focus on research and development through partnerships.
What Products and Services Does GBIM Offer?
- Develops therapeutic products for cancer and infectious diseases.
- Utilizes a proprietary Tarmogen platform to stimulate specific T-cell immune responses.
- Conducts Phase 2 trials for GS-4774, targeting chronic hepatitis B virus infection.
- Advances GI-6301 for cancers expressing the brachyury protein.
- Manages Phase 2 clinical trials for GI-6207 to treat medullary thyroid cancer.
- Progresses GI-4000 through Phase 2b trials for resected pancreas cancer and Phase 2 for non-small cell lung cancer and colorectal cancer.
- Maintains a preclinical pipeline for infectious diseases, including tuberculosis, HIV, and hepatitis D virus.
- Engages in strategic collaborations with major pharmaceutical companies like Gilead Sciences, Inc. and Celgene Corporation.
How Does GBIM Make Money?
- Primarily generates revenue through research and development activities, potentially including milestone payments from strategic collaborations.
- Relies on its proprietary Tarmogen platform to create novel immunotherapies for various diseases.
- Aims to develop and advance product candidates through clinical trials, seeking regulatory approval for commercialization.
- Partners with larger pharmaceutical companies for funding, expertise, and potential commercialization of its drug candidates.
- Focuses on intellectual property protection for its Tarmogen platform and pipeline assets.
What Industry Does GBIM Operate In?
GlobeImmune, Inc. operates within the highly specialized and capital-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by long development cycles, high regulatory hurdles, and significant R&D expenditures, with success heavily dependent on clinical trial outcomes. The broader healthcare market is experiencing trends such as increasing demand for novel therapies for chronic diseases, a growing focus on personalized medicine, and the emergence of advanced immunotherapies. GlobeImmune's Tarmogen platform positions it within the immunotherapy segment, a rapidly evolving area with substantial market potential for both cancer and infectious diseases. The competitive landscape is intense, featuring numerous large pharmaceutical companies and smaller biotech firms vying for market share with innovative drug candidates. GlobeImmune's strategy of developing a diverse pipeline and leveraging strategic partnerships is common in this industry to de-risk development and access broader resources. The company's current stage with multiple Phase 2 programs places it in a critical phase of development, where significant value inflection points can occur.
Who Are GBIM's Key Customers?
- Ultimately targets patients suffering from chronic hepatitis B, various cancers (pancreas, medullary thyroid, NSCLC, colorectal), tuberculosis, HIV, and hepatitis D.
- Pharmaceutical partners, such as Gilead Sciences, Inc. and Celgene Corporation, are key collaborators and potential licensees.
- Healthcare providers and medical institutions would be the prescribers and administrators of any approved therapies.
- Regulatory bodies (e.g., FDA) are critical stakeholders for product approval.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 12 sales, 0 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for GlobeImmune, Inc. stands at -64.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.0%, showing how much profit it generates from its asset base. A current ratio of 2.62 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
GlobeImmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.84 places it in the distress zone, a signal of elevated financial risk.
Company Profile
GlobeImmune, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Louisville, US. The company is led by CEO Donald Bellgrau. GBIM has traded publicly since 2014.
GBIM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
GBIM Latest News
No recent news available for GBIM.
GBIM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GBIM.
Price Targets
Wall Street price target analysis for GBIM.
GBIM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for GBIM; grades run from A+ (80-100) to F (below 30).
Leadership: Donald Bellgrau
Unknown
Donald Bellgrau serves in a leadership capacity at GlobeImmune, Inc., overseeing the company's operations with a team of two employees. His background is rooted in the biopharmaceutical sector, where he has gained experience in managing development-stage companies focused on innovative therapeutic platforms. His leadership is critical for a company operating with such a lean structure, requiring a deep understanding of drug development processes and strategic partnerships within the biotechnology industry.
Track Record: Under Donald Bellgrau's leadership, GlobeImmune, Inc. has maintained its focus on advancing its proprietary Tarmogen platform and a diverse pipeline of therapeutic candidates. Key achievements include the progression of GS-4774 into Phase 2 trials for hepatitis B and GI-4000 into Phase 2b trials for resected pancreas cancer, alongside other oncology and infectious disease programs. He has also overseen the continuation of strategic collaborations with major pharmaceutical partners like Gilead Sciences and Celgene Corporation, which are vital for the company's development efforts.
GBIM OTC Market Information
GlobeImmune, Inc. trades on the 'OTC Other' tier of the OTC market. This tier represents companies that do not meet the disclosure or financial requirements for higher tiers like OTCQX or OTCQB. It is generally considered the lowest and most speculative tier, often comprising companies with limited public information, distressed financials, or those not actively reporting to a U.S. regulator. Unlike companies on the NYSE or NASDAQ, which have stringent listing requirements for market capitalization, trading volume, and financial reporting, 'OTC Other' companies face minimal regulatory oversight, leading to higher risks for investors.
- OTC Tier: OTC Other
- **Limited Disclosure:** The 'Unknown' disclosure status means investors have limited access to current and comprehensive financial and operational information, making informed investment decisions challenging.
- **Low Liquidity and Price Volatility:** Trading on the 'OTC Other' tier often results in extremely low trading volumes and wide bid-ask spreads, leading to significant price volatility and difficulty in executing trades.
- **Lack of Regulatory Oversight:** Companies on this tier are subject to minimal regulatory scrutiny compared to major exchanges, increasing the risk of fraud or misleading information.
- **Market Manipulation Risk:** Low-priced, thinly traded OTC stocks are more susceptible to 'pump-and-dump' schemes and other forms of market manipulation.
- **Difficulty in Valuation:** The absence of consistent financial reporting and analyst coverage makes it exceptionally difficult to perform fundamental valuation analysis for GlobeImmune, Inc.
- Verify any available financial statements directly from the company or OTC Markets Group for recent performance.
- Research the current status and progress of all clinical trials mentioned, looking for independent verification where possible.
- Investigate the terms and current status of collaborations with Gilead Sciences and Celgene Corporation.
- Assess the company's intellectual property portfolio and patent protection for its Tarmogen platform.
- Examine any news releases or corporate filings for updates on pipeline development, financing, or corporate governance.
- Understand the company's burn rate and how long existing capital can sustain operations given its R&D focus.
- Evaluate the background and experience of key management beyond the CEO, if information is available.
- **Active Clinical Pipeline:** The company has multiple product candidates in Phase 2/2b clinical trials, indicating ongoing scientific development.
- **Strategic Collaborations:** Partnerships with reputable pharmaceutical companies like Gilead Sciences and Celgene Corporation lend credibility to its research and platform.
- **Proprietary Technology:** The Tarmogen platform suggests a foundational scientific asset that is the basis of its development efforts.
- **Established Founding Date:** Founded in 1995, the company has a history, albeit with a name change, indicating longevity in the biotech space.
- **Headquarters in a Biotech Hub:** Being headquartered in Louisville, Colorado, a region with some biotech activity, may suggest access to industry resources.
What Investors Ask About GlobeImmune, Inc. (GBIM) — Healthcare
What is the current status of GlobeImmune, Inc.'s clinical pipeline?
GlobeImmune, Inc. has several product candidates in various stages of clinical development. GS-4774 is currently in Phase 2 trials for the treatment of patients with chronic hepatitis B virus infection.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The market capitalization of $0.00B and Beta of -200.46 are highly unusual and reflect extreme market conditions or data anomalies for a publicly traded company. These figures are taken directly from the source data.
- The 'Unknown' disclosure status and 'OTC Other' tier classification indicate significant limitations in publicly available financial and operational information, impacting the depth of analysis possible.